Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Aug;84(2):517–527. doi: 10.1172/JCI114194

Treadmill exercise promotes cyclic alterations in coronary blood flow in dogs with coronary artery stenoses and endothelial injury.

J F Eidt 1, J Ashton 1, P Golino 1, J McNatt 1, L M Buja 1, J T Willerson 1
PMCID: PMC548911  PMID: 2760199

Abstract

We have previously shown in anesthetized, open-chest dogs with coronary stenosis and endothelial injury that serotonin and/or thromboxane A2 (TXA2) receptor activation play a major role in the mediation of platelet-dependent, intermittent coronary occlusion. Using a similar model in awake, closed-chest dogs, we tested the following hypotheses: (a) treadmill exercise promotes the development of cyclic flow variations in dogs with coronary stenoses and endothelial injury; (b) ventricular pacing does not induce cyclic flow variations in the same dogs; and (c) TXA2 and/or serotonin are important mediators of exercise-induced cyclic flow variations in this model. The surgical preparation consisted of the application of a hard, flow-limiting constrictor and a Doppler ultrasonic flow probe around the left coronary artery of 11 dogs. Treadmill exercise resulted in the prompt development of cyclic flow variations in all 11 dogs. Ventricular pacing at rates as high as 170 beats/min induced cyclic flow variations in only one of five dogs. Exercise-induced cyclic flow variations were abolished by TXA2 and/or serotonin receptor antagonists in all but one dog. Thus, (a) treadmill exercise promotes the development of cyclic flow variations in dogs with coronary stenoses and endothelial injury; (b) ventricular pacing does not induce cyclic flow variations in most dogs in the same model; and (c) TXA2 and/or serotonin are important mediators of cyclic flow variations in this model.

Full text

PDF
517

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiken J. W., Gorman R. R., Shebuski R. J. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins. 1979 Apr;17(4):483–494. doi: 10.1016/0090-6980(79)90001-7. [DOI] [PubMed] [Google Scholar]
  2. Ardlie N. G., Cameron H. A., Garrett J. Platelet activation by circulating levels of hormones: a possible link in coronary heart disease. Thromb Res. 1984 Nov 15;36(4):315–322. doi: 10.1016/0049-3848(84)90322-0. [DOI] [PubMed] [Google Scholar]
  3. Ashton J. H., Benedict C. R., Fitzgerald C., Raheja S., Taylor A., Campbell W. B., Buja L. M., Willerson J. T. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 1986 Mar;73(3):572–578. doi: 10.1161/01.cir.73.3.572. [DOI] [PubMed] [Google Scholar]
  4. Ashton J. H., Ogletree M. L., Michel I. M., Golino P., McNatt J. M., Taylor A. L., Raheja S., Schmitz J., Buja L. M., Campbell W. B. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation. 1987 Oct;76(4):952–959. doi: 10.1161/01.cir.76.4.952. [DOI] [PubMed] [Google Scholar]
  5. Ashton J. H., Schmitz J. M., Campbell W. B., Ogletree M. L., Raheja S., Taylor A. L., Fitzgerald C., Buja L. M., Willerson J. T. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists. Circ Res. 1986 Nov;59(5):568–578. doi: 10.1161/01.res.59.5.568. [DOI] [PubMed] [Google Scholar]
  6. Beatty C. H., Howard C. F., Jr, Caruso V. Potentiation with epinephrine of macaque platelet aggregation by other agonists: implications for studies on human atherosclerosis. Thromb Res. 1986 Feb 15;41(4):447–458. doi: 10.1016/0049-3848(86)91690-7. [DOI] [PubMed] [Google Scholar]
  7. Bolli R., Brandon T. A., Mace M. L., Jr, Weibaecher D. G. Influence of alpha-adrenergic blockade on platelet-mediated thrombosis in stenosed canine coronary arteries. Cardiovasc Res. 1985 Mar;19(3):146–154. doi: 10.1093/cvr/19.3.146. [DOI] [PubMed] [Google Scholar]
  8. Bush L. R., Campbell W. B., Buja L. M., Tilton G. D., Willerson J. T. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 1984 Jun;69(6):1161–1170. doi: 10.1161/01.cir.69.6.1161. [DOI] [PubMed] [Google Scholar]
  9. Bush L. R., Campbell W. B., Kern K., Tilton G. D., Apprill P., Ashton J., Schmitz J., Buja L. M., Willerson J. T. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res. 1984 Nov;55(5):642–652. doi: 10.1161/01.res.55.5.642. [DOI] [PubMed] [Google Scholar]
  10. Coller B. S., Folts J. D., Scudder L. E., Smith S. R. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood. 1986 Sep;68(3):783–786. [PubMed] [Google Scholar]
  11. Fitzgerald D. J., Roy L., Catella F., FitzGerald G. A. Platelet activation in unstable coronary disease. N Engl J Med. 1986 Oct 16;315(16):983–989. doi: 10.1056/NEJM198610163151602. [DOI] [PubMed] [Google Scholar]
  12. Folts J. D., Crowell E. B., Jr, Rowe G. G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation. 1976 Sep;54(3):365–370. doi: 10.1161/01.cir.54.3.365. [DOI] [PubMed] [Google Scholar]
  13. Folts J. D., Gallagher K., Rowe G. G. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation. 1982 Feb;65(2):248–255. doi: 10.1161/01.cir.65.2.248. [DOI] [PubMed] [Google Scholar]
  14. Folts J. D., Gallagher K., Rowe G. G. Hemodynamic effects of controlled degrees of coronary artery stenosis in short-term and long-term studies in dogs. J Thorac Cardiovasc Surg. 1977 May;73(5):722–727. [PubMed] [Google Scholar]
  15. Fuster V., Chesebro J. H. Mechanisms of unstable angina. N Engl J Med. 1986 Oct 16;315(16):1023–1025. doi: 10.1056/NEJM198610163151608. [DOI] [PubMed] [Google Scholar]
  16. Goldberg M. R., Robertson D. Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev. 1983 Sep;35(3):143–180. [PubMed] [Google Scholar]
  17. Golino P., Ashton J. H., Buja L. M., Rosolowsky M., Taylor A. L., McNatt J., Campbell W. B., Willerson J. T. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators. Circulation. 1989 Jan;79(1):154–166. doi: 10.1161/01.cir.79.1.154. [DOI] [PubMed] [Google Scholar]
  18. Grant J. A., Scrutton M. C. Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation. Nature. 1979 Feb 22;277(5698):659–661. doi: 10.1038/277659a0. [DOI] [PubMed] [Google Scholar]
  19. Green L. H., Seroppian E., Handin R. I. Platelet activation during exercise-induced myocardial ischemia. N Engl J Med. 1980 Jan 24;302(4):193–197. doi: 10.1056/NEJM198001243020403. [DOI] [PubMed] [Google Scholar]
  20. Hartley C. J., Hanley H. G., Lewis R. M., Cole J. S. Synchronized pulsed Doppler blood flow and ultrasonic dimension measurement in conscious dogs. Ultrasound Med Biol. 1978;4(2):99–110. doi: 10.1016/0301-5629(78)90035-2. [DOI] [PubMed] [Google Scholar]
  21. Hirsh P. D., Hillis L. D., Campbell W. B., Firth B. G., Willerson J. T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981 Mar 19;304(12):685–691. doi: 10.1056/NEJM198103193041201. [DOI] [PubMed] [Google Scholar]
  22. Laustiola K., Seppälä E., Nikkari T., Vapaatalo H. Exercise-induced increase in plasma arachidonic acid and thromboxane B2 in healthy men: effect of beta-adrenergic blockade. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):449–454. doi: 10.1097/00005344-198405000-00012. [DOI] [PubMed] [Google Scholar]
  23. Lewy R. I., Wiener L., Walinsky P., Lefer A. M., Silver M. J., Smith J. B. Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation. 1980 Jun;61(6):1165–1171. doi: 10.1161/01.cir.61.6.1165. [DOI] [PubMed] [Google Scholar]
  24. Meuleman T. R., Hill D. C., Port J. D., Stanley T. H., Pace N. L., Mohammad S. F. Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction. Crit Care Med. 1983 Aug;11(8):606–611. doi: 10.1097/00003246-198308000-00005. [DOI] [PubMed] [Google Scholar]
  25. Mills D. C., Roberts G. C. Effects of adrenaline on human blood platelets. J Physiol. 1967 Nov;193(2):443–453. doi: 10.1113/jphysiol.1967.sp008369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ogletree M. L., Harris D. N., Greenberg R., Haslanger M. F., Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther. 1985 Aug;234(2):435–441. [PubMed] [Google Scholar]
  27. Owen N. E., Feinberg H., Le Breton G. C. Epinephrine induces Ca2+ uptake in human blood platelets. Am J Physiol. 1980 Oct;239(4):H483–H488. doi: 10.1152/ajpheart.1980.239.4.H483. [DOI] [PubMed] [Google Scholar]
  28. Plow E. F., Marguerie G. A. Induction of the fibrinogen receptor on human platelets by epinephrine and the combination of epinephrine and ADP. J Biol Chem. 1980 Nov 25;255(22):10971–10977. [PubMed] [Google Scholar]
  29. Schmitz J. M., Apprill P. G., Buja L. M., Willerson J. T., Campbell W. B. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischemia. Circ Res. 1985 Aug;57(2):223–231. doi: 10.1161/01.res.57.2.223. [DOI] [PubMed] [Google Scholar]
  30. Steen V. M., Holmsen H. Synergism between thrombin and epinephrine in human platelets: different dose-response relationships for aggregation and dense granule secretion. Thromb Haemost. 1985 Oct 30;54(3):680–683. [PubMed] [Google Scholar]
  31. Strauss W. E., Cella G., Parisi A. F., Sasahara A. A. Serial studies of platelet factor 4 and beta thromboglobulin during exercise in patients with coronary artery disease. Am Heart J. 1985 Aug;110(2):293–299. doi: 10.1016/0002-8703(85)90147-4. [DOI] [PubMed] [Google Scholar]
  32. Turitto V. T., Baumgartner H. R. Platelet interaction with subendothelium in flowing rabbit blood: effect of blood shear rate. Microvasc Res. 1979 Jan;17(1):38–54. doi: 10.1016/0026-2862(79)90006-2. [DOI] [PubMed] [Google Scholar]
  33. Walinsky P., Lefer A. M., Frasca P., Santamore W. Potentiation of coronary vascular platelet adhesion by atrial pacing in the presence of arterial stenosis in dogs. J Am Coll Cardiol. 1984 May;3(5):1252–1255. doi: 10.1016/s0735-1097(84)80184-9. [DOI] [PubMed] [Google Scholar]
  34. Ware J. A., Smith M., Salzman E. W. Synergism of platelet-aggregating agents. Role of elevation of cytoplasmic calcium. J Clin Invest. 1987 Jul;80(1):267–271. doi: 10.1172/JCI113058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Willerson J. T., Campbell W. B., Winniford M. D., Schmitz J., Apprill P., Firth B. G., Ashton J., Smitherman T., Bush L., Buja L. M. Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. Am J Cardiol. 1984 Dec 1;54(10):1349–1354. doi: 10.1016/s0002-9149(84)80095-8. [DOI] [PubMed] [Google Scholar]
  36. Willerson J. T., Hillis L. D., Winniford M., Buja L. M. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol. 1986 Jul;8(1):245–250. doi: 10.1016/s0735-1097(86)80121-8. [DOI] [PubMed] [Google Scholar]
  37. van de Water A., Wouters L., Xhonneux R., Reneman S. Cardiovascular effects of ketanserin in closed-chest anesthetized dogs. Arch Int Pharmacodyn Ther. 1985 Jun;275(2):267–278. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES